medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2005, Número 5

Siguiente >>

Rev Mex Oftalmol 2005; 79 (5)


Conferencia magistral 'Sociedad Mexicana de Oftalmología' en me-moria del Dr. Enrique Graue Díaz-González. Diabetes y glaucoma.

Babayán MJI

Idioma: Español
Referencias bibliográficas: 57
Paginas: 235-241
Archivo PDF: 51.58 Kb.


FRAGMENTO

En el antiguo libro llamado El Apocalipsis, escrito por San Juan, el Evangelista, se mencionan a los universalmente conocidos Cuatro Jinetes que representaban las mayores calamidades para el género humano: la peste, la guerra, el hambre y la muerte, lo que inspiró a numerosos artistas del Renacimiento, como la hermosa xilografía del siglo XVI de Durero. Con el devenir del tiempo, cambia la apreciación de los flagelos humanos y desde el punto de vista médico y social, sin que hayan perdido su importancia estos antiguos azotes de nuestra naturaleza humana, han sido parcialmente sustituidos, o al menos hermanados, otros más modernos como el SIDA, las diferentes drogadicciones, el cáncer y la diabetes para cuyo combate se gastan cantidades astronómicas de dinero que, de cualquier manera, resultan insuficientes. Muchas exageraciones e imputaciones, algunas infundadas, se han hecho a estas enfermedades.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1. Avisar R, Bahar I, Weinberger DH. Causes of blindness in the year 2000 in Israel 2003;142(2):94-6, 160.

  2. 2. Rohrschneider K, Greim S. Epidemiology of blindness in Baden, Germany. Klin Monatsbl Augenheilkd 2004; 221(2):116-21.

  3. 3. Armaly MF, Baloglou PJ. Diabetes mellitus and the eye. 11. Intraocular pressure and aqueous outflow facility. Arch Ophthalmol 1967; 77(4):493-502.

  4. 4. Nielsen NV. The prevalence of glaucoma and ocular hypertension in type 1 and 2 diabetes mellitus. An epidemiological study of diabetes mellitus on the island of Falster, Denmark. Acta Ophthalmol (Copenh) 1983; 61(4):662-72.

  5. 5. Pang CP, Baum L, Lam DS. Hunting for disease genes in multi-functional diseases. Clin Chem Lab Med 2000; 38(9):819-25.

  6. 6. Bruttini M y cols. Mutations in the myocilin gene in families with primary open-angle glaucoma and juvenile open-angle glaucoma. Arch Ophthalmol 2003; 121(7):1034-8.

  7. 7. Silander K y cols. A Large Set of Finnish Affected Sibling Pair Families With Type 2 Diabetes Suggests Susceptibility Loci on Chromosomes 6, 11, and 14. Diabetes 2004; 53(3):821-829.

  8. 8. Mori Y y cols. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 2002; 51(4):1247-55.

  9. 9. The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 2000; 67(5):1174-85.

  10. 10. Hamaguchi K y cols. The PC-1 Q121 allele is exceptionally prevalent in the Dominican Republic and is associated with type 2 diabetes. J Clin Endocrinol Metab 2004; 89(3):1359-64.

  11. 11. Cockburn BN y cols. Insulin promoter factor-1 mutations and diabetes in Trinidad: identification of a novel diabetes-associated mutation (E224K) in an Indo-Trinidadian family. Metab 2004; 89(3):971-8.

  12. 12. Stone EM y cols. Genetic linkage of familial open angle glaucoma to chromosome 1q21-q31. Nat Genet 1993; 4(1):47-50.

  13. 13. Fossarello M y cols. Genetic mapping of autosomal dominant primary open-angle glaucoma (POAG) in Sardinia. Int Ophthalmol 1996-97; 20(1-3):1-5.

  14. 14. Ochiai Y, Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn J Ophthalmol 2002; 46(3):249-53.

  15. 15. Sato T, Roy S. Effect of high glucose on fibronectin expression and cell proliferation in trabecular meshwork cells. Invest Ophthalmol Vis Sci 2002; 43(1):170-5.

  16. 16. Kanamori A y cols. Diabetes has an additive effect on neural apoptosis in rat retina with chronically elevated intraocular pressure. Curr Eye Res 2004; 28(1):47-54.

  17. 17. The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 2000; 67(5):1174-85.

  18. 18. Kerrigan LA y cols. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol 1997; 115(8):1031-5.

  19. 19. Koss MC. Functional role of nitric oxide in regulation of ocular blood flow. Eur J Pharmacol 1999; 374(2):161-74.

  20. 20. Downiw NM, Heath RW. Métodos estadísticos aplicados. 5a ed. Harla, México, 1986. 95-114.

  21. 21. Clark CV, Mapstone R. The prevalence of diabetes mellitus in the family history of patients with primary glaucoma. Doc Ophthalmol 1986; 62(2):161-3.

  22. 22. Elisaf M, Kitsos G, Bairaktari E, Kalaitzidis R, Kalogeropoulos C, Psilas K. Metabolic abnormalities in patients with primary open-angle glaucoma. Acta Ophthalmol Scand 2001; 79(2):129-32.

  23. 23. Klein BE, Klein R, Jensen SC. The Beaver Dam Eye Study. Open-angle glaucoma and older-onset diabetes. Ophthalmology 1994; 101(7):1173-7.

  24. 24. Dielemans I, de Jong PT, Stolk R, Vingerling JR, Grobbee DE, Hofman A. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population. The Rotterdam Study. Ophthalmology 1996; 103(8):1271-5.

  25. 25. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. The European glaucoma prevention study design and baseline description of the participants. Ophthalmology 2002; 109(9):1612-21.

  26. 26. Lee PP, Feldman ZW, Ostermann J, Brown DS, Sloan FA. Longitudinal prevalence of major eye diseases. Arch Ophthalmol 2003; 121(9):1303-10.

  27. 27. Zeiter JH, Shin DH. Diabetes in primary open-angle glaucoma patients with inferior visual field defects. Graefes Arch Clin Exp Ophthalmol 1994; 232(4):205-10.

  28. 28. Mitchel P, Smith W, Chey T, Healey PR. Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology 1997; 104(4):712-8.

  29. 29. Uhm KB, Shin DH. Glaucoma risk factors in primary open-angle glaucoma patients compared to ocular hypertensives and control subjects. Korean J Ophthalmol 1992; 6(2):91-9.

  30. 30. Wang N, Peng Z, Fan B, Liu Y, Dong X, Liang X, Luan J. Case control study on the risk factors of primary open angle glaucoma in China. Zhonghua Liu Xing Bing Xue Za Zhi 2002; 23(4):293-6.

  31. 31. Tielsch JM, Katz J, Quigley HA, Javitt JC, Sommer A. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology 1995; 102(1):48-53.

  32. 32. Clark CV. Diabetes mellitus in primary glaucomas. Ann Acad Med Singapore 1989;18(2):190-4.

  33. 33. Leske MC, Nemesure B, He Q, Wu SY, Fielding Hejtmancik J, Hennis A. Patterns of open-angle glaucoma in the Barbados Family Study. Ophthalmology 2001; 108(6):1015-22.

  34. 34. Jonas JB, Grundler AE. Prevalence of diabetes mellitus and arterial hypertension in primary and secondary open-angle glaucomas. Graefes Arch Clin Exp Ophthalmol 1998; 236(3):202-6.

  35. 35. Konareva-Kostianeva M. Family history and some other factors in primary open angle glaucoma. Folia Med (Plovdiv) 1998; 40(4):78-81.

  36. 36. Ellis JD, Evans JM, Ruta DA, Baines PS, Leese G, MacDonald TM, Morris AD. Glaucoma incidence in an unselected cohort of diabetic patients: is diabetes mellitus a risk factor for glaucoma? DARTS/MEMO collaboration. Diabetes Audit and Research in Tayside Study. Medicines Monitoring Unit. Br J Ophthalmol 2000; 84(11):1218-24.

  37. 37. Clark CV, Mapstone R. Progression of impaired glucose tolerance to diabetes mellitus in patients with primary glaucoma and ocular hypertension. Diabet Med 1986; 3(3):226-9.

  38. 38. Zghal I, Jeddi A, Hadj Alouane WB, Malouche N, Ayed S, Gaigi S. Primary open- angle glaucoma and diabetes. Tunis Med 2000; 78(8-9):518-21.

  39. 39. Dannheim R, Westenberger W. Reasons for postoperative deterioration of visual fields in cases of advanced primary open-angle glaucoma. Klin Monatsbl Augenheilkd 1981; 178(1):65-7.

  40. 40. Seddon JM y col. Case Control Study of ocular hypertension. Arch Ophthalmol 1983; 101: 891-4.

  41. 41. Mirza GE, Karakucuk S, Temel E. Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. J Glaucoma 2000; 9(1):45-50.

  42. 42. Yamamoto T, Kitazawa Y, Noma A, Maeda S, Kato A, Ando Y, Ido T y col. The effects of the beta-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J Glaucoma 1996; 5(4):252-7.

  43. 43. van Beek LM, Mulder M, van Haeringen NJ, Kijlstra A. Topical ophthalmic beta blockers may cause release of histamine through cytotoxic effects on inflammatory cells. Br J Ophthalmol 2000; 84(9):1004-7.

  44. 44. Inoue K, Okugawa K, Kato S, Inoue Y, Oshika T, Amano S. Ocular factors relevant to keratoepitheliopathy in glaucoma patients with and without diabetes mellitus. Jpn J Ophthalmol 2003; 47(3):287-90.

  45. 45. Grodum K, Heijl A, Bengtsson B. Optic disc hemorrhages and generalized vascular disease. J Glaucoma 2002; 11(3):226-30.

  46. 46. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am J Ophthalmol 2002; 134(4):481-98.

  47. 47. Schwartz AL, Van Veldhuisen PC, Gaasterland DE, Ederer F, Sullivan EK, Cyrlin MN. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. Am J Ophthalmol 1999; 127(1):8-19.

  48. 48. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol 2002t; 134(4):499-512.

  49. 49. Sung VC, Butler TK, Vernon SA. Non-enhanced trabeculectomy by non-glaucoma specialists: are results related to risk factors for failure? Eye 2001; 15(Pt 1):45-51.

  50. 50. Hugkulstone CE, Smith LF, Vernon SA. Trabeculectomy in diabetic patients with glaucoma. Eye 1993; 7( Pt 4):502-6.

  51. 51. Lehmann OJ, Bunce C, Matheson MM, Maurino V, Khaw PT, Wormald R. Risk factors for development of post-trabeculect-

  52. omy endophthalmitis. Br J Ophthalmol 2000; 84(12):1349-53.

  53. 52. Edmunds B, Bunce CV, Thompson JR, Salmon JF, Wormald RP. Factors associated with success in first-time trabeculectomy for patients at low risk of failure with chronic open-angle glaucoma. Ophthalmology 2004; 111(1):97-103.

  54. 53. Fuller JR, Bevin TH, Molteno AC, Vote BJ, Herbison P. Anti-inflammatory fibrosis suppression in threatened trabeculect-

  55. omy bleb failure produces good long term control of intraocular pressure without risk of sight threatening complications. Br J Ophthalmol 2002; 86(12):1352-4.

  56. 54. Pollak A, Katz H, Oliver M, Zalish M. The course after cataract extraction, intraocular lens implantation, and trabeculectomy for patients with diabetes. Ophthalmic Surg Lasers 1996; 27(7):595-9.

  57. 55. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am J Ophthalmol 2002; 134(4):481-98.




2020     |     www.medigraphic.com